

# Oh I Forgot! Let's Focus on ADHD

Lucinda Whitney, DNP, APRN, PMHNP-BC  
Clinical Assistant Professor / PMHNP Program Coordinator  
KUMC School of Nursing

## History of ADHD

- 1902: ADHD first described
- 1923: ADHD could result from head trauma
- 1937: Benzadrine (amphetamin.e) to treat childhood migraine  
-Found benefit for attention & behavior issues
- 1962: Ritalin - approved for kids
- 1967: National Institute of Mental Health  
-First study to assess effect of stimulants on hyperactive children
- 1970's: Cylert, Dextrostate, & Dexedrine
- 1980's: Ritalin Slow Release
- 1990 to present: Stimulant & non stimulant treatment


Center for Disease Control & Prevention [CDC], (2017)

## Objectives

Participants will

- Self report, via electronic evaluation, increased confidence in working with patients who need common pharmacologic management for ADHD

## State Based Prevalence Data




Percent of Kids Aged 4-17 Ever Diagnosed with Attention-Deficit/Hyperactivity Disorder

CDC, (2017)

## Disclosures

- I have no pertinent financial disclosures
- Information provided here is for on label application
- This presentation is for educational purposes only & is not a substitute for an individual's judgment or a clinicians practice protocol

## ADHD is a Clinical Diagnosis



American Academy of Pediatrics, (2011)

- Psychological & neuro-psych testing may be useful in complicated clinical presentations; however, testing is NOT typically indicated for the routine evaluation & diagnosis of ADHD.
- A thorough clinical interview & evaluation is the st&ard.

American Academy of Pediatrics. (2011)  
American Psychiatric Association. [APA] (2013)

## DSM-V Diagnostic Criteria: ADHD

- Loses things necessary for tasks or activities
  - House key, homework, textbooks, phone...
- Easily distracted by extraneous stimuli
  - Noise in the classroom (talking, pencil tapping), or for teenagers unrelated thoughts
- Forgetful in daily activities
  - Chores (dishes, trash, feed animals)
  - Brush teeth, flush toilet

APA. (p. 59, 2013)

## DSM-V Diagnostic Criteria: ADHD

Inattention Symptoms (at least 6 symptoms required for patients 16 & younger; 5 symptoms for 17 & older)

- Fails to give close attention to details or makes careless mistakes in schoolwork, etc.
  - Missed details, rushes through work, doesn't read or fully read the instructions
- Difficulty sustaining attention
  - Boring activities, "lectures, conversations, lengthy reading"
- Does not seem to listen when spoken to directly
  - Daydreaming, "mind seems elsewhere"

APA. (p. 59, 2013)

## PBS: Misunderstood Minds



## DSM-V Diagnostic Criteria: ADHD

- Does not follow through on instructions & fails to finish schoolwork, chores, etc.
  - Easily sidetracked, doesn't complete activity/chore
- Difficulty organizing tasks & activities
  - Struggles with sequential activities, messy, poor time management
- Avoids tasks requiring sustained mental effort
  - School work, homework, writing papers

APA. (p. 59, 2013)

## ADHD Diagnostic Criteria (cont.)

- Hyperactivity-Impulsivity Symptoms (at least 6 symptoms required)
  - Fidgets with hands/feet or squirms in seat
  - Leaves seat in classroom or in other situations in which remaining seated is expected
  - Runs about or climbs inappropriately
  - Difficulty playing or engaging in activities quietly

APA. (p. 60, 2013)

## ADHD Diagnostic Criteria (cont.)

### Hyperactivity-Impulsivity Symptoms

- Often "on the go" or acts as if "driven by a motor"
- Talks excessively
- Blurts out answers
  - Tries to finish others sentences
- Difficulty waiting in lines or awaiting turn
- Interrupts or intrudes on others

APA, (p. 60, 2013)

## Gender Differences

### Boys

- More hyperactivity
- More disruptive
- More externalizing behaviors
- ADHD more common in boys

### Girls

- Less hyperactivity
- Less disruptive
- More internal
- Girls diagnosed with combined type are often seriously impacted

Loeber & Keenan (1994)

## ADHD Diagnostic Criteria (cont.)

- Symptoms present before age 12
- Clinically significant impairment in social or academic/occupational functioning
- Some symptoms that cause impairment are present in 2 or more settings
  - School, home, recreational settings
- Not due to another disorder
  - Anxiety, Mood Disorder, ODD, or Autism

APA, (2013)

## Girls ADHD

- Hyperactivity is easily identified, but not inattention
  - Rating tools can be skewed to hyperactivity
- Outcomes for girls can be more serious than what boys experience
  - Academics
    - Lower academic expectations
  - Social
    - Inattentive girls may be ignored
    - Hyperactive girls may be excluded/avoided
- Social & cultural expectation of girls to be cooperative & compliant
  - Seen & not heard



## Subtypes

- Combined Type
  - Inattentive & hyperactivity/impulsivity
    - Most common subtype
- Inattentive Subtype – more difficult to diagnose
  - Clinical levels of inattention only
  - Often not identified until middle school
    - Executive functioning demands increase
    - Kids have insight to report/endorse symptoms
- Hyperactive/Impulsive Subtype
  - Very young & more common prior to starting school

APA, (2013)

## Sleep Issues

- Hyper arousal at bedtime
  - I need a drink
  - I need a snack
  - I need to use the bathroom
  - I need a hug
  - I need you
- Once asleep, hyper kids typically stay asleep

### Clinical Pearl

- Girls with ADHD can change their clothes a lot & throw their clean clothes in the dirty laundry
- Room cleaning is a major problem because its hard to sequence & follow through

Symptoms (continued)	Never	Occasionally	Often	Very Often
11. Necessity to do things others postpone	0	1	2	3
12. Has used a weapon that can cause serious harm (that knive, knife, gun)	0	1	2	3
13. Is physically violent or assaultive	0	1	2	3
14. Has deliberately set fire to cause damage	0	1	2	3
15. Has broken into someone else's home, business or car	0	1	2	3
16. Has stayed out all night without permission	0	1	2	3
17. Has run away from home overnight	0	1	2	3
18. Has broken someone else's car or property	0	1	2	3
19. Is fearful, anxious, or worried	0	1	2	3
20. Is teased or by new things or is of teasing remarks	0	1	2	3
21. Feels worthless or inferior	0	1	2	3
22. Is sad, lonely, or depressed	0	1	2	3
23. Feels lonely, unloved, or unwanted; complains that no one loves him or her	0	1	2	3
24. Is sad, unhappy, or depressed	0	1	2	3
25. Is self-conscious in class or in school	0	1	2	3

Performance	Somewhat of a			
	Excellent	Above Average	Average	Problematic
26. Overall school performance	2	2	2	3
27. Reading	2	2	2	3
28. Writing	2	2	2	3
29. Discipline	2	2	2	3
30. Relationship with parents	2	2	2	3
31. Relationship with siblings	2	2	2	3
32. Relationship with peers	2	2	2	3
33. Participation in organized activities (e.g. sports)	2	2	2	3

Comments:

### Assessment Tools


#### V&erbilt

- Parent & teacher scales
- 47 questions / 15 minutes to fill out
- Assesses
  - Inattention & hyperactivity
  - Conduct & oppositional defiant qualities
  - Anxiety traits
  - Performance ratings

#### Conner's Rating Scale

- Proprietary
- Clinician dependent

### State Based Prevalence Data



Kids Aged 4-17 Currently with ADHD Receiving Medication Treatment  
CDC, (2017)

Symptoms	Never	Occasionally	Often	Very Often
1. Does not pay attention to details or makes careless mistakes	0	1	2	3
2. Has difficulty staying on task, restless or fidgets	0	1	2	3
3. Does not listen when spoken to directly	0	1	2	3
4. Does not listen through when given directions and has to be reminded of facts to understand	0	1	2	3
5. Has difficulty organizing tasks and activities	0	1	2	3
6. Sometimes loses or forgets what is needed to complete an activity	0	1	2	3
7. Does things haphazardly or makes careless mistakes	0	1	2	3
8. Is easily distracted by noise or other people	0	1	2	3
9. Has difficulty staying on task or organizing or making plans	0	1	2	3
10. Talks too much or runs around or climbs when inappropriate	0	1	2	3
11. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
12. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
13. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
14. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
15. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
16. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
17. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
18. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
19. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
20. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
21. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
22. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
23. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
24. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
25. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
26. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
27. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
28. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
29. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
30. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
31. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
32. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
33. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
34. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
35. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
36. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
37. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
38. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
39. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
40. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
41. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
42. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
43. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
44. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
45. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
46. Has difficulty playing or participating in sports or leisure activities	0	1	2	3
47. Has difficulty playing or participating in sports or leisure activities	0	1	2	3

Figure 1. FDA-Approved Pediatric Age Ranges and Indications for Stimulant and Related Medications

Medication	Age Range (Years)														
	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
amphetamines/dextroamphetamine mixed salts[2]															
amphetamine/dextroamphetamine mixed salts ER[3]															
atomoxetine[4]															
lisdexamfetamine[5, 6]															
clonidine ER[7]															
coaximethylphenidate[8]															
dextroamphetamine[9]															
dextroamphetamine SR[10]															
guanfacine ER[11]															
lisdexamfetamine[12]															
methamphetamine[13]															
methylphenidate [14, 15, 16, 17, 18, 19, 20, 21, 22]															

Legend: ADHD (shaded), comorbidities (checkered), comorbidities (dotted)

CMS, (2015)

### Methylphenidate (MPH)

Drug	Dose	Peak / Duration	Profile
Methylphenidate Immediate-release ( <i>Ritalin, Methylin</i> )	Tablets 5, 10, 20mg Chewable 2.5, 5, 10mg Liquid 5mg/5mL, 10mg/5 mL	• Onset 20 min. • Early peak • 4 hrs.	• TID dosing • Start 5mg • MAX 60mg
Methylphenidate Sustained-Release ( <i>Ritalin SR, Methylin SR, Metadate ER, generic SR</i> )	Tablets 10, 20mg	• Onset 30 min. • 4-6 hrs.	• Once per day or BID dosing • Use in stead of IR • Start 10mg • MAX 60mg
Methylphenidate ER Concerta Aptensio	Tablets 18, 27, 36, 54mg	• Onset 30 min. • 8-12 hrs.	• Once daily • Start 18 - 27mg • MAX 72mg

ADHD: Kids age 6 & older MPH is up to 2mg/kg per day

Leehey, (2017), Stahl, (2014)

### Dextroamphetamine

Drug	Dose	Peak / Duration	Profile
Dexedrine <i>D. Amphetamine</i>	Tablet 5, 10mg	• Onset 20-30 min. • Peak 2 hrs.. • Duration 4 hrs..	• Stronger & longer duration than MTH • Start: Ages 3-5 • 2.5mg per day • Ages 6+ • 5-10mg day • BID - TID • MAX 40mg
Dexedrine Spansules SR	Capsule 5, 10, 15mg	• Onset 60-90 min.. • Peak 1-2 hrs.. • Duration 8 hrs..	• Once daily • Less rebound than in IR • 50% IR + 50% XR • MAX 40 mg
ProCentra	Liquid 1mg/mL	• 20-30 min. • Duration 4-6 hrs.	• Start, ages & dosing same as Dexedrine

Leehey, (2017), Stahl, (2014)

### Methylphenidate (MTH)

Drug	Dose	Peak / Duration	Profile
Metadate CD	Capsule 10, 20, 30, 40, 50, 60mg	• Early peak • 8hrs..	• Once daily • Metadate: 30% IR + 70% ER
Ritalin LA	Capsule 10, 20, 30, & 40mg	• Two strong peaks (early & at 4 hrs). • 8-12 hrs.	• Ritalin LA: 50% IR + 50% ER • Start 20mg • MAX 60mg
Aptensio XR	Tablets 10, 15, 20, 30, 40, 50, 60mg	• Onset 30-45 min. • 8-12 hrs.	• Once daily • 40% IR + 60% XR • Beads: sprinkled on food • Start 10 mg • MAX 60mg
Quillivant XR	Liquid - time release 5mg/5mL	• Onset 30 min. • 12 hrs.	• Once daily • 30% IR + 70% ER • Start 20mg • MAX 60mg
Quillichew ER	Tablets 20, 30, 40mg (20 & 30 are scored)		

Leehey, (2017), Stahl, (2014)

### Dextroamphetamine + Amphetamine

Drug	Dose	Peak / Duration	Profile
Adderall IR	Tablet double scored	• Onset 30-60 min. • Peak 1-2 hrs..	• BID-TID dosing • Start 5-10mg per day
Amphetamine Salts <i>D, L Amphetamine</i>	5, 7.5, 10, 12.5, 15, 20, 30mg	• Duration 6-8 hrs..	• 25/75 Levo/Dex • MAX 30-40 mg
Adderall XR	Capsule 5, 10, 15, 20, 25, 30mg	• Duration 10-12 hrs..	• 50% IR + 50% XR • MAX 30mg
Evekeo IR	Oral disintegrating tab 5, 10mg	• Onset 30 min. • Duration 4-6	• Similar to Adderall IR • 50/50 Levo/Dex
Adenys XR ODT	Oral disint. tab 3.1, 6.3, 9.4, 12.5, 15.7, 18.4mg	• Onset 30 min. • Duration 10-12 hrs..	• Similar to Adderall XR • Only disintegrating XR

Leehey, (2017), Stahl, (2014)

### Methylphenidate (MTH)

Drug	Dose	Peak / Duration	Profile
Daytrana Transdermal Patch	Patch 10, 15, 20, 30mg 10 = 1.1 mg/hr 15 = 1.6mg/hr 20 = 2.2 mg/hr 30 = 3.3mg/hr	• Onset 1 hr • Peak 8-10 hrs. • Duration up to 2 hrs., after removal • Remove after 8-12 hrs..	• 1 patch per day to hip. • Avoid oral dosing • OTC topical steroid for skin irritation • MAX 30mg
Focalin Dexmethylphenidate	Tablet 2.5, 5, 10mg	• Onset 30 min. • Duration 4-5 hrs..	• BID dosing • Start 5mg BID • MAX generally 20mg per day
Focalin XR	Tablet 5, 10, 15, 20, 25, 30, 35, 40mg	• Onset 30-60min. • Peak 90 min. & 4 hrs.. • Duration 8 hrs..	• Once Daily • Start 5-10mg • 50% IR + 50% XR • MAX 40mg

Leehey, (2017), Stahl, (2014)

### D, L Amphetamine & Lisdexamfetamine

Drug	Dose	Onset/Duration	Profile
Dyanavel XR	Oral suspension 2.5mg/ml 1ml = 1cc	• Onset 30 min. • Duration 10-12 hrs..	• Similar to Adderall XR in liquid form • No refrigeration • Once a day • Start 2.5mg • Max 20mg

#### Lisdexamfetamine

Vyvanse lisdexamfetamine	Capsule 10, 20, 30, 40, 50, 60, 70mg	• Onset 30 min. • Duration 8-12 hrs..	• Pro Drug = lower diversion • Once a day • Can be dissolved in water, yogurt, OJ • Start 20-30mg • Max 70mg
--------------------------	--------------------------------------	--	--

Leehey, (2017), Stahl, (2014)

## Stimulant Side Effects

### More Common

- Decreased appetite
  - Typically at lunch
- Rebound hunger in evening
- Delayed sleep onset
  - Often associated with taking late in the day
- Anxiety that subsides

### Less Common

- Headache
- Stomach ache
- "Whiney" as med wears off in afternoon
- Irritability "meaner"
- Weight loss
- Tics
  - Eye blinking
  - Nose scrunching
  - Mouth opening

Leehey, (2016)

## Non Stimulant

Kapvay: Clonidine ER

- FDA approved from ADHD
- Dosing:
  - 1<sup>st</sup> week: 0.1 mg at HS
  - 2<sup>nd</sup> week: 0.1mg BID
  - MAX: 0.1mg q am & 0.2mg q HS
- Monitor BP when starting & discontinuing medication



## Non Stimulant

Strattera (Atomoxetine)

- Norepinephrine reuptake inhibitor
- Tablets: 10, 18, 25, 40, 60, 80, 100mg
- Kids  $\leq$  70kg
  - 0.5mg/kg/day - after 3 days - 1.2 mg/kg/day
  - Starts at HS- typically sedating
  - Divided doses once acclimated to medication
- Kids  $\geq$  70kg
  - 40mg @ HS
  - Increase in 3-5 days in divided doses

## Non Stimulant

Tenex /Guanfacine IR

- Dose 0.5mg - 4 mg per day
- Start - 0.5 - 1mg depending on age

Intuniv / Guanfacine XR

- 1mg - 4 mg per day
- Start 1mg for one week, 2mg second week...
- Take one month to titrate to 4mg

Profile

- Longer half life than Clonidine - improved tolerability
- Dose at HS to increase tolerability
- Monitor BP when starting & discontinuing medication

## Non Stimulant

Clonidine: Oral &amp; transdermal patch (Catapres-TTS)

- 0.05mg to 0.4mg
- Start 0.05mg @ HS
- Titrate over 2-4 weeks
- Monitor BP closely, especially when discontinuing
- Helpful for "hyper-arousal"

NOTE: High risk of medication error r/t decimal point  
Order tablets as 0.1mg - Take ½ tablet...

## Prescription Medical Food

Vayarin (Lipirinen): Diet therapy

- Reportedly
- DHA (Omega-3 fatty acid docosahexaenoic acid)
  - Critical to brain health & functioning
  - Declining levels may play a role in poor cognition

Lauritzen, et al., (2016)

- Children with ADHD typically have lower level of Omega-3 LC-PUFA
  - Long chain Polyunsaturated fatty acid
  - Reported to increased DHA bioavailability in the brain
    - Omega 3 = 19% bioavailability
    - Vayarin = 43% bioavailability
  - Takes up to 90 days to build up in the system

Vayarin, (2017)

## Starting Pharmacotherapy

### What to Consider

- Cardiac Risk Assessment
  - Rates for sudden death in patients treated with stimulant & persons in the general population are similar
  - Conflicting data as to whether stimulants increase risk of cardiac events. Hamilton et al. (2009)
- Baseline EKG
- Child & family history of heart problems
- Kids under 6 years
- Practice protocols

### How to Start

- Parent/Child Preferences
- Formulation
- Dosing options
- Social issues
  - Older kids don't like going to the school nurse
  - Kids at risk for misuse or diversion
- Establish tolerability
- Start lowest dose or lowest dose that you think is going to be effective

## Older Child Case

Lana: 12 y/o, 5<sup>th</sup> grade

- Grades deteriorated as the expectation for her to be more responsible & organized increased
  - Procrastinates doing her work - Reads & can't remember what she read
  - Forgets to do her homework &/or forgets to put it in her backpack &/or forgets to return work to her teacher
- 62" tall; 115 lbs; healthy, no cardiac history, no sleep problems, no anxiety
- Taking Methylphenidate ER 18mg
  - Improvement noted, but not sufficient. Evenings are rough
- PLAN
- Increase MTH ER 27mg + MTH 5mg at 4pm

## Behavioral Management

Kids: Learn to control themselves & promotes self efficacy

- Most effective in kids  $\leq 6$  y/o when provided at home by parent
- Strategies to simplify/shorten/emphasize tasks
- Positive & negative reinforcement

### Advantages

- Enduring benefit without side effects
- May be important as children reach adolescence & become less likely to continue their medication

### Disadvantages

- More effort-intensive & more expensive than medication
- Access to therapy - fewer mental health providers
- Adherence rates are low

Felt et al., (2011)

## Young Adolescent

Jayden: 14 y/o, 8<sup>th</sup> grade - Middle school

- Treated for ADHD since the 3<sup>rd</sup> grade
- Has been on MTH, Focalin, & most recently Adderall
- Takes Adderall XR 30mg for six months
- Adderall helpful, but loses efficacy in early afternoon
- Plays sport after school & is really struggling to focus
- Dreads doing his homework, parents have to closely monitor
- 56", 150 lbs., healthy, no cardiac history, no sleep problems
- PLAN
  - Continue Adderall XR 30mg
  - Start Adderall XR 10mg at 12 noon

## Young Child Case

Liam: 5 years old, 1<sup>st</sup> grade

- Frequent trouble in kindergarten for bossing peers or pushing while standing in line; Liam wants to be first
- His level of hyperactivity gets on his families nerves
- Unable to settle down at night
  - In & out of bed. Takes a hour to get him to sleep
  - Once asleep, Liam stays asleep
- 85<sup>th</sup> percentile, healthy, no family history of heart problems, ERG is normal
- PLAN:
  - Dexedrine 5mg q am & titrate to AM & 12 noon
  - Consider Dexedrine 2.5mg at 4pm
  - Melatonin to help ease into sleep. If ineffective consider adding low dose clonidine or guanfacine at bedtime

## Adolescent Case

Aden: 17 y/o senior in HS

- Has been treated for ADHD since the 5th grade
- Diagnosed with Generalized Anxiety in 10th grade
  - Took SSRI & stopped due to sexual side effect
- GAD- worries make it difficult for him to get to sleep
  - 1-2 hour delay
  - Has limited electronics prior to bedtime
  - Tired in the morning
- 72", 170 lbs, healthy, no cardiac history
- Taking Vyvanse 50mg q day with "okay" results
- PLAN
  - Intuniv 1mg at HS for 7 nights then increase to 2mg at HS & continue through next appointment. Target dose is 3-4mg

## Case To Refer

Isaac: 8 y/o, 2<sup>nd</sup> grade

- ADHD, C, ODD, & Fetal Alcohol Syndrome
  - Very hyperactive, hyper verbal, has poor frustration tolerance, & poor impulse control
  - Difficult to manage in the classroom. Gets angry when he can't have his way
  - Irritability & reactivity more consistent with a mood disorder, but grandma down plays that as "just being a boy"
- 50<sup>th</sup> percentile for height & weight, EKG is normal
- PLAN
  - Start Adderall 5mg AM & 12 noon; Start Tenex 0.5mg at HS
    - Recommended MTH due to less likely to cause agitation
    - Grandma preferred Adderall - "I've heard stories about Ritalin"
    - 3 weeks later - STOP Adderall due to increased anger & aggression

## References

- American Academy of Pediatrics. (2011). *Implementing the key action statements: An algorithm & explanation for process of care for the evaluation, diagnosis, treatment, & monitoring of ADHD in children & adolescents. Supplement*. Retrieved from <http://pediatrics.appublications.org/content/suppl/2011/10/11/peds.2011.2254.PS1.2.pdf>
- American Psychiatric Association. (2013). *Diagnostic & Statistical Manual of Mental Disorder*, (5<sup>th</sup> ed.). Washington DC: Author.
- Centers for Disease Control & Prevention. (2017). State-based prevalence data of parent reported ADHD diagnosis by a health care provider. Retrieved from <https://www.cdc.gov/ncbddd/adhd/prevalence.html#current>
- Centers for Medicare & Medicaid Services. (2015, October). *Stimulant & related medications: Use in pediatric patients*. Retrieved from <https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/downloads/stim-pediatric-factsheet11-18.pdf>
- Fok, B.T., Buerman, B., Christner, J. G., Kuchbar, P., & Van Harrison, R. (2011). Diagnosis & management of ADHD in children. *American Family Physician*, 90, 456-464. Retrieved from <http://www.aafp.org/afp/2011/11/11/p456.html>
- Hamilton, R., Gray, C., Bélanger S.A., Warren, A. E., Gow, R. M., Sanatani, S., Schadtler, R. (2009). Cardiac risk assessment before the use of stimulant medication in children & youth: A joint position statement by the Canadian paediatric society, the Canadian cardiovascular society & the Canadian academy of child & adolescent psychiatry. *Journal of the Canadian Academy of Child & Adolescent Psychiatry*, 18, 349-355. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765311/>

## Summary

- ADHD is brain-based disorder that can result in lifelong impairment in functioning.
- Stimulant medications with behavior therapy is evidence-based treatment for ADHD.
- Combined treatment has the greatest impact on normalizing social, academic, & vocational outcomes.

## References

- Lauritzen, L., Brambilla, P., Mazzocchi, A., Harsdorf, L. B. S., Ciappalino, V., & Agostoni, C. (2016). DHA effects in brain development & functioning. *Nutrients*, 8, 1-17. DOI: 10.3390/nu8101006. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728620/>
- Leehey, K. (2016). *Medications for attention deficit hyperactivity disorders*. Retrieved August 1, 2017 from [www.leeheyind.com/adhdia/h.html](http://www.leeheyind.com/adhdia/h.html)
- Loeber, R., & Keenan, K. (1994). Interactions between & its comorbid conditions. Effects of age & gender. *Clinical Psychology Review*, 14, 497-523.
- Pharmacist's Letter/Prescriber's Letter. (2016, March) *PI detail document, comparison of ADHD medications*. Retrieved from <http://rx.theapclettersresearch.com>
- Stahl, S. M. (2014). *Essential psychopharmacology: The prescribers guide*, (5<sup>th</sup> ed.). Cambridge, UK: Cambridge University Press.
- Valler, J. A., Kalenchuk, A. L., & McLennan, J. D. (2014). Behavioral treatment recommendation in clinical practice guidelines for attention-deficit/hyperactivity disorder: A scoping review. *Child & Adolescent Mental Health*, 19, 251-258. DOI: 10.1111/camh.12062

## Questions

